AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025
AVITA Medical (NASDAQ: RCEL) announced the presentation of 16 abstracts at the American Burn Association (ABA) 2025 Annual Meeting in Phoenix, showcasing data across their wound care portfolio including RECELL®, Cohealyx™, and PermeaDerm®.
Key findings include:
- Pre-clinical study on Cohealyx showing support for wound bed vascularization within 7 days
- Largest real-world analysis of over 6,000 RECELL-treated patients demonstrating increasing adoption and consistent clinical utility
- New clinical data on PermeaDerm as an effective temporary wound coverage solution
- Randomized multicenter trial results showing PermeaDerm reduces dressing change frequency and supports early wound healing
The company aims to address the needs of over 450,000 Americans requiring medical treatment for burn injuries annually, focusing on earlier wound closure and reduced procedural complexity.
AVITA Medical (NASDAQ: RCEL) ha annunciato la presentazione di 16 abstract alla Conferenza Annuale dell'American Burn Association (ABA) 2025 a Phoenix, mostrando dati relativi al loro portafoglio di prodotti per la cura delle ferite, tra cui RECELL®, Cohealyx™ e PermeaDerm®.
I principali risultati includono:
- Studio preclinico su Cohealyx che dimostra il supporto per la vascolarizzazione del letto della ferita entro 7 giorni
- La più grande analisi nel mondo reale di oltre 6.000 pazienti trattati con RECELL, che dimostra un'adozione crescente e un'utilità clinica costante
- Nuovi dati clinici su PermeaDerm come soluzione efficace per la copertura temporanea delle ferite
- Risultati di uno studio clinico multicentrico randomizzato che mostrano come PermeaDerm riduca la frequenza dei cambi di medicazione e supporti la guarigione precoce delle ferite
L'azienda mira a soddisfare le esigenze di oltre 450.000 americani che richiedono trattamenti medici per lesioni da ustione ogni anno, concentrandosi su una chiusura delle ferite più rapida e una riduzione della complessità procedurale.
AVITA Medical (NASDAQ: RCEL) anunció la presentación de 16 resúmenes en la Reunión Anual de la American Burn Association (ABA) 2025 en Phoenix, mostrando datos de su cartera de cuidados de heridas, incluyendo RECELL®, Cohealyx™ y PermeaDerm®.
Los hallazgos clave incluyen:
- Estudio preclínico sobre Cohealyx que muestra apoyo para la vascularización del lecho de la herida en 7 días
- El análisis más grande del mundo real de más de 6,000 pacientes tratados con RECELL, demostrando una adopción creciente y una utilidad clínica consistente
- Nuevos datos clínicos sobre PermeaDerm como una solución efectiva para la cobertura temporal de heridas
- Resultados de un ensayo multicéntrico aleatorizado que muestran que PermeaDerm reduce la frecuencia de cambio de apósitos y apoya la curación temprana de heridas
La empresa tiene como objetivo abordar las necesidades de más de 450,000 estadounidenses que requieren tratamiento médico por lesiones por quemaduras cada año, enfocándose en un cierre de heridas más temprano y una reducción de la complejidad del procedimiento.
AVITA Medical (NASDAQ: RCEL)는 2025년 미국 화상 협회(ABA) 연례 회의에서 16개의 초록을 발표했다고 발표하며, RECELL®, Cohealyx™, PermeaDerm®을 포함한 상처 치료 포트폴리오에 대한 데이터를 선보였습니다.
주요 발견 사항은 다음과 같습니다:
- Cohealyx에 대한 전임상 연구로, 7일 이내에 상처 바닥의 혈관화를 지원함을 보여줌
- 6,000명 이상의 RECELL 치료 환자에 대한 가장 큰 실제 분석으로, 증가하는 채택과 일관된 임상 유용성을 입증함
- 일시적인 상처 덮개 솔루션으로서 PermeaDerm에 대한 새로운 임상 데이터
- PermeaDerm가 드레싱 교체 빈도를 줄이고 조기 상처 치유를 지원한다는 무작위 다기관 시험 결과
회사는 매년 450,000명 이상의 미국인이 화상 치료를 필요로 하는 요구를 충족하는 것을 목표로 하며, 더 빠른 상처 닫힘과 절차의 복잡성 감소에 중점을 두고 있습니다.
AVITA Medical (NASDAQ: RCEL) a annoncé la présentation de 16 résumés lors de la Réunion Annuelle de l'American Burn Association (ABA) 2025 à Phoenix, mettant en avant des données sur leur portefeuille de soins des plaies, y compris RECELL®, Cohealyx™ et PermeaDerm®.
Les principales conclusions incluent:
- Étude préclinique sur Cohealyx montrant un soutien à la vascularisation du lit de la plaie en 7 jours
- La plus grande analyse du monde réel de plus de 6 000 patients traités avec RECELL, démontrant une adoption croissante et une utilité clinique constante
- Nouvelles données cliniques sur PermeaDerm comme solution efficace pour la couverture temporaire des plaies
- Résultats d'un essai multicentrique randomisé montrant que PermeaDerm réduit la fréquence des changements de pansement et soutient la guérison précoce des plaies
L'entreprise vise à répondre aux besoins de plus de 450 000 Américains nécessitant un traitement médical pour des blessures par brûlure chaque année, en se concentrant sur une fermeture des plaies plus précoce et une réduction de la complexité des procédures.
AVITA Medical (NASDAQ: RCEL) gab die Präsentation von 16 Abstracts auf dem Jahrestreffen der American Burn Association (ABA) 2025 in Phoenix bekannt, in dem Daten aus ihrem Wundversorgungsportfolio, einschließlich RECELL®, Cohealyx™ und PermeaDerm®, vorgestellt werden.
Wichtige Ergebnisse umfassen:
- Präklinische Studie zu Cohealyx, die Unterstützung für die Vaskularisierung des Wundbettes innerhalb von 7 Tagen zeigt
- Die größte Analyse aus der Praxis mit über 6.000 mit RECELL behandelten Patienten, die eine zunehmende Akzeptanz und konsistente klinische Nützlichkeit demonstriert
- Neue klinische Daten zu PermeaDerm als effektive temporäre Wundabdeckungslösung
- Ergebnisse einer randomisierten multizentrischen Studie, die zeigen, dass PermeaDerm die Häufigkeit von Verbandswechseln reduziert und die frühe Wundheilung unterstützt
Das Unternehmen zielt darauf ab, die Bedürfnisse von über 450.000 Amerikanern zu adressieren, die jährlich medizinische Behandlung aufgrund von Brandverletzungen benötigen, wobei der Fokus auf einer früheren Wundschließung und einer reduzierten Verfahrenskomplexität liegt.
- Large-scale validation with over 6,000 patients demonstrating RECELL's clinical success
- Positive clinical trial results for PermeaDerm showing reduced dressing changes and improved monitoring
- Promising pre-clinical data for Cohealyx showing rapid wound healing within 7 days
- None.
Insights
AVITA's ABA 2025 presentation of 16 abstracts represents meaningful clinical validation for their expanded wound care portfolio. The 6,000+ patient retrospective analysis on RECELL is particularly significant as it constitutes one of the largest real-world datasets in burn care, demonstrating growing clinical adoption and consistent utility across burn centers.
The pre-clinical data showing Cohealyx supports wound bed vascularization with potential for definitive closure by day 7 suggests meaningful clinical advancement in treatment timelines. Meanwhile, the randomized multicenter trial comparing PermeaDerm to traditional silver-based dressings provides compelling evidence of reduced dressing change frequency and enhanced wound monitoring capabilities.
These collective findings strengthen AVITA's competitive position in the $450,000+ annual patient burn treatment market. The company is effectively building a comprehensive evidence base across its product portfolio, which typically accelerates adoption curves in the medical device sector. The data's focus on practical outcomes like reduced procedural complexity and earlier wound closure directly addresses key pain points for providers and supports potential for expanded reimbursement coverage.
The continued investment in clinical evidence across multiple product lines indicates a strategic commitment to establishing AVITA as the standard of care in burn treatment through differentiated clinical outcomes rather than competing solely on pricing.
Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDerm
VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. The presentations will feature real-world and clinical data on AVITA Medical’s wound care portfolio, including RECELL®, Cohealyx™, and PermeaDerm®, showcasing the company’s expanded evidence base and commitment to improving outcomes in burn and wound management. Visit AVITA Medical at booth #513 to learn more.
Each year, more than 450,000 Americans require medical treatment for burn injuries, often facing prolonged hospitalization, multiple procedures, and complex wound management. AVITA Medical’s technologies are designed to address these challenges by supporting earlier wound closure and reduce procedural complexity, aligning with the company’s mission to improve healing timelines and patient outcomes.
“The breadth of data that is being presented at ABA 2025 reflects our commitment to improving patient outcomes,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “With more than 30,000 patients treated globally and a growing body of real-world and clinical evidence across our portfolio, our technologies are helping providers deliver better outcomes and set new standards of care in burn and wound treatment.”
Key Findings Featured at ABA 2025
Abstracts on AVITA Medical’s technology highlight in vivo research on Cohealyx, real-world insights on RECELL, and new clinical findings on PermeaDerm, further supporting the company’s role in advancing patient care and optimizing treatment strategies for acute wound care. Key findings include:
- In Vivo Research on Cohealyx
A new pre-clinical study evaluating the integration and efficacy of the dermal collagen matrix in full-thickness wounds suggests it supports wound bed vascularization, and readiness for definitive closure as early as 7 days.
- Real-World RECELL Data
A national retrospective analysis of over 6,000 patients treated with RECELL represents the largest known real-world dataset in burn care utilizing the technology. The study demonstrates increasing adoption and consistent clinical utility across burn centers, highlighting trends in patient outcomes, evolving treatment protocols, and its impact on wound healing and patient outcomes.
- PermeaDerm as a Wound Temporizer
New clinical data reinforces the role of PermeaDerm as a temporary wound coverage solution in burn management, providing stability between procedures, preserving wound integrity, and offering an alternative to higher-priced cadaver skin.
- Randomized Control Trial Evaluating PermeaDerm
A randomized multicenter trial comparing PermeaDerm to a traditional silver-based dressing reports PermeaDerm reduces the frequency of dressing changes, enables continuous wound monitoring due to its transparency, and supports early wound healing in partial-thickness burns.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute both Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “would,” “may,” “will,” “believe,” “continue,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.com
FAQ
What are the key findings from AVITA Medical's RECELL real-world data presented at ABA 2025?
How does Cohealyx perform in wound healing according to RCEL's latest research?
What advantages does PermeaDerm show in AVITA Medical's latest clinical trial?
How many abstracts is AVITA Medical (RCEL) presenting at ABA 2025?
